MX2021014629A - Compuestos tetraciclicos como inhibidores de cdc7. - Google Patents

Compuestos tetraciclicos como inhibidores de cdc7.

Info

Publication number
MX2021014629A
MX2021014629A MX2021014629A MX2021014629A MX2021014629A MX 2021014629 A MX2021014629 A MX 2021014629A MX 2021014629 A MX2021014629 A MX 2021014629A MX 2021014629 A MX2021014629 A MX 2021014629A MX 2021014629 A MX2021014629 A MX 2021014629A
Authority
MX
Mexico
Prior art keywords
tetracyclic compounds
cdc7 inhibitors
cdc7
inhibitors
tetracyclic
Prior art date
Application number
MX2021014629A
Other languages
English (en)
Inventor
Gang Li
Lihong Hu
Shuhui Chen
Zhibo Zhang
Charles Z Ding
Lun Lu
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2021014629A publication Critical patent/MX2021014629A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

Una nueva clase de compuestos tetracíclicos que actúan como inhibidores de Cdc7; se divulga específicamente un compuesto representado por la fórmula (I), sus isómeros o sus sales farmacéuticamente aceptables. (ver Fórmula).
MX2021014629A 2019-05-30 2020-05-29 Compuestos tetraciclicos como inhibidores de cdc7. MX2021014629A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910464384 2019-05-30
CN201910491339 2019-06-06
CN201911128459 2019-11-18
PCT/CN2020/093480 WO2020239107A1 (zh) 2019-05-30 2020-05-29 作为Cdc7抑制剂的四并环类化合物

Publications (1)

Publication Number Publication Date
MX2021014629A true MX2021014629A (es) 2022-02-23

Family

ID=73553516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014629A MX2021014629A (es) 2019-05-30 2020-05-29 Compuestos tetraciclicos como inhibidores de cdc7.

Country Status (12)

Country Link
US (1) US20220235068A1 (es)
EP (1) EP3978501A4 (es)
JP (1) JP2022534316A (es)
KR (1) KR20220027883A (es)
CN (2) CN113874379B (es)
AU (1) AU2020281411A1 (es)
BR (1) BR112021023886A2 (es)
CA (1) CA3142202A1 (es)
IL (1) IL288472A (es)
MX (1) MX2021014629A (es)
SG (1) SG11202113212YA (es)
WO (1) WO2020239107A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114127077B (zh) * 2019-08-20 2023-08-01 正大天晴药业集团股份有限公司 用作Cdc7抑制剂的四并环类化合物
KR20230116005A (ko) * 2020-11-30 2023-08-03 치아타이 티안큉 파마수티컬 그룹 주식회사 Cdc7 억제제로 사용되는 염 형태 및 이의 결정 형태

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517949A (ja) * 2003-02-17 2006-08-03 ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ キナーゼ阻害剤としての四環系ピラゾール誘導体、前記誘導体の製造方法、および前記誘導体を含む医薬組成物
EP1621539A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
MX353500B (es) * 2010-02-17 2018-01-16 Takeda Pharmaceuticals Co Compuesto heterociclico.
TWI738748B (zh) * 2016-03-28 2021-09-11 日商武田藥品工業有限公司 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形
JP2020508675A (ja) * 2017-03-01 2020-03-26 武田薬品工業株式会社 Ｃｄｃ７阻害剤の効果を予測する方法

Also Published As

Publication number Publication date
BR112021023886A2 (pt) 2022-01-18
CN113874379A (zh) 2021-12-31
US20220235068A1 (en) 2022-07-28
CA3142202A1 (en) 2020-12-03
EP3978501A4 (en) 2023-05-24
CN116425770A (zh) 2023-07-14
AU2020281411A1 (en) 2022-01-06
EP3978501A1 (en) 2022-04-06
CN113874379B (zh) 2023-03-31
JP2022534316A (ja) 2022-07-28
SG11202113212YA (en) 2021-12-30
WO2020239107A1 (zh) 2020-12-03
KR20220027883A (ko) 2022-03-08
IL288472A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
MX2022007969A (es) Inhibidores de egfr.
MX2022011283A (es) Compuestos pirimidoheterocíclicos y aplicación de los mismos.
CR20210032A (es) Compuestos
UY38057A (es) Inhibidores de sarcómero cardíaco
MX2010013557A (es) Nuevos compuestos triciclicos.
MX2021013531A (es) Inhibidores de cdk.
WO2019132561A8 (ko) 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
ES2657549T3 (es) Piridopirazinas sustituidas como nuevos inhibidores de SYK
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2021007017A (es) Inhibidor de la 15-pgdh.
ZA202201503B (en) Urea compound for antagonizing lpa1 receptor
AU2018316542A1 (en) Indole derivatives as histone demethylase inhibitors
PH12016500838A1 (en) Isoxazolines as therapeutic agents
MX2021014629A (es) Compuestos tetraciclicos como inhibidores de cdc7.
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
PH12019550154A1 (en) Azetidine derivative
MY193239A (en) Novel b-lactamase inhibitors
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
CO2024000221A2 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2021013981A (es) Inhibidores de la cinasa aurora y usos de los mismos.
EA202091481A1 (ru) Замещенные алкиниленовые соединения в качестве противораковых агентов
MX2022001044A (es) Inhibidor de sglt2/dpp4 y su aplicacion.
PH12021550248A1 (en) Borate of azetidine derivative
EA202193248A1 (ru) ТЕТРАЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Cdc7
MX2022005415A (es) Compuesto de imidazolidinona, metodo de preparacion del mismo y uso del mismo.